These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 21305148)

  • 1. Reactivity of an antimetastatic organometallic ruthenium compound with metallothionein-2: relevance to the mechanism of action.
    Casini A; Karotki A; Gabbiani C; Rugi F; Vašák M; Messori L; Dyson PJ
    Metallomics; 2009 Sep; 1(5):434-41. PubMed ID: 21305148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydrolysis study of the bifunctional antitumour compound RAPTA-C, [Ru(eta6-p-cymene)Cl2(pta)].
    Scolaro C; Hartinger CG; Allardyce CS; Keppler BK; Dyson PJ
    J Inorg Biochem; 2008 Sep; 102(9):1743-8. PubMed ID: 18582946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stability of an organometallic ruthenium-ubiquitin adduct in the presence of glutathione: relevance to antitumour activity.
    Hartinger CG; Casini A; Duhot C; Tsybin YO; Messori L; Dyson PJ
    J Inorg Biochem; 2008 Dec; 102(12):2136-41. PubMed ID: 18834634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tuning the hydrophobicity of ruthenium(II)-arene (RAPTA) drugs to modify uptake, biomolecular interactions and efficacy.
    Scolaro C; Chaplin AB; Hartinger CG; Bergamo A; Cocchietto M; Keppler BK; Sava G; Dyson PJ
    Dalton Trans; 2007 Nov; (43):5065-72. PubMed ID: 17992291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro ruthenation of human breast cancer suppressor gene 1 (BRCA1) by the antimetastasis compound RAPTA-C and its analogue CarboRAPTA-C.
    Ratanaphan A; Temboot P; Dyson PJ
    Chem Biodivers; 2010 May; 7(5):1290-302. PubMed ID: 20491084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ESI-MS characterisation of protein adducts of anticancer ruthenium(II)-arene PTA (RAPTA) complexes.
    Casini A; Mastrobuoni G; Ang WH; Gabbiani C; Pieraccini G; Moneti G; Dyson PJ; Messori L
    ChemMedChem; 2007 May; 2(5):631-5. PubMed ID: 17366652
    [No Abstract]   [Full Text] [Related]  

  • 7. Development of organometallic ruthenium-arene anticancer drugs that resist hydrolysis.
    Ang WH; Daldini E; Scolaro C; Scopelliti R; Juillerat-Jeannerat L; Dyson PJ
    Inorg Chem; 2006 Oct; 45(22):9006-13. PubMed ID: 17054361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CZE-ICP-MS as a tool for studying the hydrolysis of ruthenium anticancer drug candidates and their reactivity towards the DNA model compound dGMP.
    Groessl M; Hartinger CG; Dyson PJ; Keppler BK
    J Inorg Biochem; 2008; 102(5-6):1060-5. PubMed ID: 18222004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterizing activation mechanisms and binding preferences of ruthenium metallo-prodrugs by a competitive binding assay.
    Artner C; Holtkamp HU; Hartinger CG; Meier-Menches SM
    J Inorg Biochem; 2017 Dec; 177():322-327. PubMed ID: 28739166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Top-down characterization of proteins and drug-protein complexes using nanoelectrospray tandem mass spectrometry.
    Mandal R; Li XF
    Rapid Commun Mass Spectrom; 2006; 20(1):48-52. PubMed ID: 16308874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomolecule binding vs. anticancer activity: reactions of Ru(arene)[(thio)pyr-(id)one] compounds with amino acids and proteins.
    Meier SM; Hanif M; Kandioller W; Keppler BK; Hartinger CG
    J Inorg Biochem; 2012 Mar; 108():91-5. PubMed ID: 22420927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metal binding to brain-specific metallothionein-3 studied by electrospray ionization mass spectrometry.
    Palumaa P; Eriste E; Kruusel K; Kangur L; Jörnvall H; Sillard R
    Cell Mol Biol (Noisy-le-grand); 2003 Jul; 49(5):763-8. PubMed ID: 14528913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Organometallic ruthenium anticancer complexes inhibit human glutathione-S-transferase π.
    Lin Y; Huang Y; Zheng W; Wang F; Habtemariam A; Luo Q; Li X; Wu K; Sadler PJ; Xiong S
    J Inorg Biochem; 2013 Nov; 128():77-84. PubMed ID: 23942162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reaction of Zn7metallothionein with cis- and trans-[Pt(N-donor)2Cl2] anticancer complexes: trans-Pt(II) complexes retain their N-donor ligands.
    Knipp M; Karotki AV; Chesnov S; Natile G; Sadler PJ; Brabec V; Vasák M
    J Med Chem; 2007 Aug; 50(17):4075-86. PubMed ID: 17665893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes.
    Scolaro C; Bergamo A; Brescacin L; Delfino R; Cocchietto M; Laurenczy G; Geldbach TJ; Sava G; Dyson PJ
    J Med Chem; 2005 Jun; 48(12):4161-71. PubMed ID: 15943488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantification of bindings of organometallic ruthenium complexes to GSTπ by mass spectrometry.
    Lin Y; Huang Y; Zheng W; Wu K; Luo Q; Zhao Y; Xiong S; Wang F
    J Inorg Biochem; 2015 May; 146():44-51. PubMed ID: 25769011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA interactions of monofunctional organometallic ruthenium(II) antitumor complexes in cell-free media.
    Novakova O; Chen H; Vrana O; Rodger A; Sadler PJ; Brabec V
    Biochemistry; 2003 Oct; 42(39):11544-54. PubMed ID: 14516206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anthracene-tethered ruthenium(II) arene complexes as tools to visualize the cellular localization of putative organometallic anticancer compounds.
    Nazarov AA; Risse J; Ang WH; Schmitt F; Zava O; Ruggi A; Groessl M; Scopelitti R; Juillerat-Jeanneret L; Hartinger CG; Dyson PJ
    Inorg Chem; 2012 Mar; 51(6):3633-9. PubMed ID: 22394115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trans-cis-cis-[RuCl2(DMSO)2(2-amino-5-methyl-thiazole)2], (PMRu52), a novel ruthenium(II) compound acting as a strong inhibitor of cathepsin B.
    Mura P; Camalli M; Casini A; Gabbiani C; Messori L
    J Inorg Biochem; 2010 Feb; 104(2):111-7. PubMed ID: 19939460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular uptake and subcellular distribution of ruthenium-based metallodrugs under clinical investigation versus cisplatin.
    Groessl M; Zava O; Dyson PJ
    Metallomics; 2011 Jun; 3(6):591-9. PubMed ID: 21399784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.